Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine...

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Triple-negative breast cancer (TNBC) remains a challenging malignancy with limited targeted therapies.
• Hexadecylphosphocholine (HePC), also known as miltefosine, is a clinically relevant anticancer alkylphosphocholine with demonstrated efficacy.
• Understanding the precise molecular mechanisms of HePC's action in TNBC is crucial for optimizing its therapeutic application.

Purpose of the Study:

• To elucidate the molecular signaling pathways governing cell death modes induced by HePC in TNBC cells.
• To investigate the role of Fas signaling in HePC-mediated apoptosis and non-apoptotic cell death.
• To determine whether Fas acts as a pro-apoptotic or protective factor in the context of HePC treatment.

Main Methods:

• Treatment of TNBC cell lines with HePC.
• Analysis of cell death modes (apoptotic and non-apoptotic).
• Manipulation of Fas expression using siRNA and overexpression techniques.
• Assessment of Fas/Fas ligand signaling capacity.

Main Results:

• HePC induces cell-type-dependent apoptotic and non-apoptotic cell death in TNBC.
• Fas expression levels and signaling capacity do not dictate the preference for apoptosis.
• Fas functions as a cell-protective factor, rather than a pro-apoptotic one, in HePC-sensitive TNBC cells.

Conclusions:

• HePC exhibits multi-modal anticancer capabilities in TNBC cells.
• Fas signaling plays a protective role, contrary to its typical pro-apoptotic function, in HePC-induced cell death.
• These findings provide insights for developing targeted therapeutic strategies against TNBC using HePC.